These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 2427409)
21. [Clinical experience with heparinoid sodium pentosan polysulfate (SP54) in the treatment of cerebral ischemia]. Szirmai I; Fendler K; Kollár L; Romhányi M Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):278-88. PubMed ID: 2427411 [TBL] [Abstract][Full Text] [Related]
22. Profibrinolytic and anticoagulant properties of the pentosan polysulphate derivative bego 0391. Klöcking HP; Hauptmann J; Richter M Pharmazie; 1991 Jul; 46(7):543-4. PubMed ID: 1723804 [No Abstract] [Full Text] [Related]
23. Influence on the clotting mechanism of sodium pentosan polysulfate (SP54) in comparison to commercial beef lung sodium heparin. Vinazzer H; Haas S; Stemberger A Thromb Res; 1980 Oct; 20(1):57-68. PubMed ID: 6163222 [No Abstract] [Full Text] [Related]
24. Effect of pentosan polysulphate on endothelial regeneration. Herbert JM; Floutard D; Paul R; Maffrand JP Pathol Biol (Paris); 1989 Sep; 37(7):847-50. PubMed ID: 2483584 [TBL] [Abstract][Full Text] [Related]
25. Effect of pentosan polysulphate in minipigs with experimental pulmonary emboli. Sedlarik K; Klöcking HP; Mönch C Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):126-31. PubMed ID: 2459006 [TBL] [Abstract][Full Text] [Related]
26. Localization of the inhibitory site(s) of pentosan polysulphate in blood coagulation. Wagenvoord R; Hendrix H; Soria C; Hemker HC Thromb Haemost; 1988 Oct; 60(2):220-5. PubMed ID: 2464199 [TBL] [Abstract][Full Text] [Related]
27. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects. MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807 [TBL] [Abstract][Full Text] [Related]
28. On the thrombolytic effect of pentosan polysulphate in animals. Klöcking HP; Richter M; Markwardt F Pharmazie; 1988 Jun; 43(6):440-1. PubMed ID: 2463649 [No Abstract] [Full Text] [Related]
29. Effects of various doses of SP 54 on fibrinolytic activity in patients with thrombotic diseases. Losonczy H; Nagy I; Dávid M Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(3):388-93. PubMed ID: 2465236 [TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Petersen KR Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723 [TBL] [Abstract][Full Text] [Related]
31. [Pharmacology of a heparinoid derived from pentosan]. Lansen J; Diner H Agressologie; 1983 Dec; 24(12):591-5. PubMed ID: 6199994 [No Abstract] [Full Text] [Related]
32. Diurnal variation of the fibrinolytic system. Grimaudo V; Hauert J; Bachmann F; Kruithof EK Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085 [TBL] [Abstract][Full Text] [Related]
33. [Importance of the structure of the clot in thrombolysis]. Soria C; Soria J; Mirshahi M; Desvignes P; Bonnet P; Caen JP Ann Biol Clin (Paris); 1987; 45(2):207-11. PubMed ID: 2441630 [TBL] [Abstract][Full Text] [Related]
34. Anticoagulant activities of pentosan polysulphate (Hémoclar) due to release of hepatic triglyceride lipase (HTGL). Barrowcliffe TW; Gray E; Merton RE; Dawes J; Jennings CA; Hubbard AR; Thomas DP Thromb Haemost; 1986 Oct; 56(2):202-6. PubMed ID: 2433786 [TBL] [Abstract][Full Text] [Related]
35. Sex differences in the determinants of fibrinolytic activity. MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046 [TBL] [Abstract][Full Text] [Related]
36. Fibrinolytic activity in blood is distributed over a cellular and the plasma fraction which can be modulated separately. van Giezen JJ; Chung-A-Hing JE; Vegter CB; Bouma BN; Jansen JW Thromb Haemost; 1994 Dec; 72(6):887-92. PubMed ID: 7740459 [TBL] [Abstract][Full Text] [Related]
37. [Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human]. Seifried E; Böck F; Tanswell P; Rijken DC; Kluft C; Heimpel H Klin Wochenschr; 1988; 66 Suppl 12():40-9. PubMed ID: 2450222 [TBL] [Abstract][Full Text] [Related]
38. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro. Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599 [TBL] [Abstract][Full Text] [Related]
39. Clot structure modification by fondaparinux and consequence on fibrinolysis: a new mechanism of antithrombotic activity. Varin R; Mirshahi S; Mirshahi P; Kierzek G; Sebaoun D; Mishal Z; Vannier JP; Yvonne Borg J; Simoneau G; Soria C; Soria J Thromb Haemost; 2007 Jan; 97(1):27-31. PubMed ID: 17200767 [TBL] [Abstract][Full Text] [Related]
40. [Fibrinolytic system of animals repeatedly and chronically administered plasminogen tissue activator]. Shimonaeva EE; Liutova LV; Andreenko GV Vopr Med Khim; 1981; 27(6):823-8. PubMed ID: 7199779 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]